☆ 4.7 Meeting Abstract

Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.

JOURNAL OF CLINICAL ONCOLOGY (2019)

期刊

JOURNAL OF CLINICAL ONCOLOGY

卷 37, 期 15, 页码 -

出版社

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2019.37.15_suppl.2616

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia

J. R. Rivas, Y. Liu, S. S. Alhakeem, J. M. Eckenrode, F. Marti, J. P. Collard, Y. Zhang, K. A. Shaaban, N. Muthusamy, G. C. Hildebrandt, R. A. Fleischman, L. Chen, J. S. Thorson, M. Leggas, S. Bondada

Summary: In CLL, T-cell dysfunction is driven by molecules like PD-L1 and IL-10. Suppressing IL-10 using a novel inhibitor enhances antitumor T-cell activity and responses to ICB. Targeting IL-10 provides a novel strategy to improve immunotherapies in CLL patients who do not respond well to current therapies.

LEUKEMIA (2021)

添加到收藏夹

Review Oncology

Immune-Related Adverse Events of the Gastrointestinal System

Steven Nicolaides, Alex Boussioutas

Summary: Immunotherapy is an effective cancer treatment that activates the immune system to target and destroy cancer cells. However, the use of immune checkpoint inhibitors is often limited by immune-related adverse events. This review focuses on the management and emerging therapies for immune-related adverse events in the gastrointestinal system.

CANCERS (2023)

添加到收藏夹

Review Oncology

Aging, cancer, and antitumor immunity

Hideki Ikeda, Yosuke Togashi

Summary: Aging leads to changes in the immune system, causing dysregulated responses and increased susceptibility to diseases in elderly individuals. Despite some understanding, detailed mechanisms of immunosenescence remain unclear. ICIs have shown efficacy in older cancer patients, but may be less effective in very old patients with more frequent toxicities.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Nanoscience & Nanotechnology

T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy

Yihui Zhai, Jinming Wang, Tianqun Lang, Ying Kong, Rong Rong, Ying Cai, Wei Ran, Fengqin Xiong, Chao Zheng, Yanke Wang, Yang Yu, Helen H. Zhu, Pengcheng Zhang, Yaping Li

Summary: Researchers have developed a novel nanoparticle platform that enhances tumor immunity while reducing immunosuppression. This platform effectively increases levels of IFNs within the tumor and inhibits tumor growth.

NATURE NANOTECHNOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma

Xiaopeng Peng, Ziwen Yu, Goverdhan Surineni, Bulian Deng, Meizhu Zhang, Chuan Li, Zhiqiang Sun, Wanyi Pan, Yao Liu, Shenglan Liu, Bin Yu, Jianjun Chen

Summary: In this study, a series of novel HDAC6 inhibitors containing polycyclic aromatic rings were discovered and evaluated for their pharmacological activities. Compound 10c showed high inhibitory activity against HDAC6 and selectivity over HDAC3. It also exhibited decent antiproliferative activity against cancer cell lines and demonstrated potential as an anti-cancer agent. Furthermore, the combination of 10c with a PD-L1 inhibitor showed promising results in reducing tumor burden and enhancing the anti-tumor immune response.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2023)

添加到收藏夹

Review Oncology

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Rosmely Hernandez, Thomas R. Malek

Summary: Cancer vaccines have the potential to enhance T cell-mediated antitumor immunity and may be crucial in improving the response to current immunotherapies. However, as monotherapies, cancer vaccines have not been very effective and require the use of adjuvants and immune modulators to enhance their efficacy.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Tumor Microenvironment-Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy

Yuting Tang, Qian Xu, Liang Hu, Xiaomei Yan, Xiaomin Feng, Asumi Yokota, Weinan Wang, Di Zhan, Durga Krishnamurthy, David E. Ochayon, Lijun Wen, Li Huo, Huimin Zeng, Yingwan Luo, Mark Wunderlich, Jiwang Zhang, Eric Vivier, Jianfeng Zhou, Stephen N. Waggoner, Gang Huang

Summary: R-spondin 3 expression is associated with favorable prognosis and enhances infiltration and function of NK cells and T cells in tumors, leading to tumor regression, and also increases tumor sensitivity to anti-PD-1 therapy.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Expression Levels of Three Key Genes CCNB1, CDC20, and CENPF in HCC Are Associated With Antitumor Immunity

Tengfei Si, Zhenlin Huang, Yuanhang Jiang, Abigail Walker-Jacobs, Shaqira Gill, Robert Hegarty, Mohammad Hamza, Shirin Elizabeth Khorsandi, Wayel Jassem, Nigel Heaton, Yun Ma

Summary: Upregulation of CCNB1, CDC20, and CENPF is commonly observed in HCC and associated with the p53 signal pathway, and their hepatic mRNA expression levels are strongly correlated with prognosis and have high AUC values. These genes are positively correlated with Th1/Th17 cytokines such as IFN-gamma, TNF-alpha, and IL-17, as well as with the count of CD4(pos) and CD8(pos) T cells. Additionally, in the HCC microenvironment, these genes show a positive correlation with inhibitory checkpoint molecules including PD-1, CTLA-4, and TIM-3.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis

Miho Kono, Malek Shatila, Guofan Xu, Yang Lu, Antony Mathew, Wasay Mohajir, Krishnavathana Varatharajalu, Wei Qiao, Anusha S. Thomas, Yinghong Wang

Summary: This retrospective study explored the relationship between obesity and immune checkpoint inhibitor-induced immune-related adverse events (irAEs). The findings showed that lower body mass index (BMI) was associated with a more severe disease course. Obesity did not significantly alter the course of irAEs or impact overall survival. Importantly, the study supported the use of BMI as an indicator of adiposity in cancer patients.

CANCERS (2023)

添加到收藏夹

Review Immunology

The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application

Xu Han, Dan Zang, Dan Liu, Jun Chen

Summary: With the advent of tumor immunotherapy, the effect of gut microbiota on Immune Checkpoint Inhibitor-Mediated Colitis (IMC) has become a major research focus. Gut microbiota from different phyla can modulate the innate and acquired immunity of tumor patients, influencing Immune Checkpoint Inhibitor-Mediated Colitis.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Chemistry, Medicinal

Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options

Carmen Portenkirchner, Peter Kienle, Karoline Horisberger

Summary: In recent years, anti-tumor immunotherapies, specifically immune checkpoint inhibitors (ICIs), have shown significant progress. However, ICIs have also introduced a new class of adverse events, such as colitis, which are more common in vulnerable patient groups like IBD patients and the elderly. Colitis, while associated with a favorable oncological outcome, is also the most common irAE leading to discontinuation of therapy, particularly in these vulnerable groups. New therapeutic approaches, such as fecal transplantation or ileostomy creation, may offer promising alternatives for severe cases of colitis.

PHARMACEUTICALS (2021)

添加到收藏夹

Review Immunology

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis

Guanzhou Zhou, Nana Zhang, Ke Meng, Fei Pan

Summary: This article discusses the interaction between gut microbiota and immune checkpoint inhibitor-related colitis, focusing on potential pathogenic mechanisms and interventions.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Engineering, Biomedical

pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer

Su -Wen Zhu, Mengjie Ye, Xianbin Ma, Zhi-Zhong Wu, Shu-Cheng Wan, Shao-Chen Yang, Hao Li, Zhigang Xu, Zhi-Jun Sun

Summary: In this study, pH-responsive nanomicelles (PDO NPs) were designed by loading a small molecular pro-drug synthesized by the Src inhibitor dasatinib and the chemotherapy drug oxaliplatin into the amphiphilic block copolymer iPDPA to enhance the immunological effects of chemotherapy for HNSCC. These nanomicelles can efficiently accumulate in tumor cells and achieve pH-responsive drug release. The PDO NPs can induce pyroptosis of tumor cells and potentiate antitumor immunity in subcutaneous and syngenetic orthotopic HNSCC mouse models, presenting a promising strategy to enhance immunochemotherapy for HNSCC.

ACTA BIOMATERIALIA (2022)

添加到收藏夹

Review Immunology

Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management

Liansha Tang, Jialing Wang, Nan Lin, Yuwen Zhou, Wenbo He, Jiyan Liu, Xuelei Ma

Summary: This article summarizes the relevant studies on checkpoint inhibitor colitis caused by immune checkpoint inhibitors and discusses future research directions.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma

Aditi Kothari, Matthew J. Flick

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal disease with a low 5-year survival rate due to its aggressive nature and late-stage diagnosis. The coagulation system plays a crucial role in PDAC progression and dissemination, promoting tumor growth and spread.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Oncology

Sentinel Lymph Node Biopsy for Extremity and Truncal Soft Tissue Sarcomas: A Systematic Review of the Literature

Emily Z. Keung, Kate J. Krause, Jessica Maxwell, Carol D. Morris, Aimee M. Crago, Matthew T. Houdek, John Kane, Valerae Lewis, Dario Callegaro, Benjamin Miller, Alexander J. Lazar, Rebecca Gladdy, Chandrajit P. Raut, Nicola Fabbri, Waddah Al-Refaie, Mark Fairweather, Sandra L. Wong, Christina L. Roland

Summary: Regional lymph node metastasis (RLNM) is uncommon in patients with soft tissue sarcoma (STS), although certain STS subtypes are more prone to RLNM. The impact of node-positive disease on patient survival is still controversial. There is ongoing debate about the benefits of sentinel lymph node biopsy (SLNB) in STS patients. Further multicenter prospective studies are needed to determine the true incidence and potential benefits of SLNB in patients with clinically occult RLNM.

ANNALS OF SURGICAL ONCOLOGY (2023)

添加到收藏夹

Editorial Material Oncology

ASO Visual Abstract: Re-Excision After Unplanned Excision of Soft Tissue Sarcoma Is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease

Raymond S. Traweek, Allison N. Martin, Nikita F. Rajkot, B. Ashleigh Guadagnolo, Andrew J. Bishop, Alexander J. Lazar, Emily Z. Keung, Keila E. Torres, Kelly K. Hunt, Barry W. Feig, Christina L. Roland, Christopher P. Scally

ANNALS OF SURGICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness

Yize Li, Tung-Shing M. Lih, Saravana M. Dhanasekaran, Rahul Mannan, Lijun Chen, Marcin Cieslik, Yige Wu, Rita Jiu-Hsien Lu, David J. Clark, Iga Koodziejczak, Runyu Hong, Siqi Chen, Yanyan Zhao, Seema Chugh, Wagma Caravan, Nataly Naser Al Deen, Noshad Hosseini, Chelsea J. Newton, Karsten Krug, Yuanwei Xu, Kyung-Cho Cho, Yingwei Hu, Yuping Zhang, Chandan Kumar-Sinha, Weiping Ma, Anna Calinawan, Matthew A. Wyczalkowski, Michael C. Wendl, Yuefan Wang, Shenghao Guo, Cissy Zhang, Anne Le, Aniket Dagar, Alex Hopkins, Hanbyul Cho, Felipe da Veiga Leprevost, Xiaojun Jing, Guo Ci Teo, Wenke Liu, Melissa A. Reimers, Russell Pachynski, Alexander J. Lazar, Arul M. Chinnaiyan, Brian A. Van Tine, Bing Zhang, Karin D. Rodland, Gad Getz, D. R. Mani, Pei Wang, Feng Chen, Galen Hostetter, Mathangi Thiagarajan, W. Marston Linehan, David Fenyo, Scott D. Jewell, Gilbert S. Omenn, Rohit Mehra, Maciej Wiznerowicz, Ana I. Robles, Mehdi Mesri, Tara Hiltke, Eunkyung An, Henry Rodriguez, Daniel W. Chan, Christopher J. Ricketts, Alexey I. Nesvizhskii, Hui Zhang, Li Ding

Summary: By integrating histopathologic, proteogenomic, and metabolomic analyses, this study reveals the inter- and intratumoral heterogeneity of clear cell renal cell carcinomas (ccRCCs). It identifies high-risk disease subsets based on tumor grade, BAP1 mutation, genome instability, hypermethylation, and protein glycosylation signature. RNA sequencing provides insights into gene signatures and potential targeted therapies, while in vitro cell line studies validate the efficacy of inhibiting identified phosphoproteome targets.

CANCER CELL (2023)

添加到收藏夹

Article Oncology

Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time

Tuyen Duong Thanh Nguyen, Yan Wang, Tuyen N. Bui, Rossana Lazcano, Davis R. Ingram, Min Yi, Varshini Vakulabharanam, Linjie Luo, Marc A. Pina, Cansu Karakas, Mi Li, Nicole M. Kettner, Neeta Somaiah, Peter J. Hougton, Osama Mawlawi, Alexander J. Lazar, Kelly K. Hunt, Khandan Keyomarsi

Summary: Treatment strategies with CDK4/6 inhibitors followed by DNA-damaging agents showed synergistic killing of Rb-positive sarcomas and can be noninvasively monitored using functional imaging and serum biomarkers. This approach provides a potential avenue for novel targeted therapies in sarcomas with intact Rb signaling.

CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

Changes in outcomes and factors associated with survival in melanoma patients with brain metastases

Merve Hasanov, Denai R. Milton, Alicia Bea Davies, Elizabeth Sirmans, Chantal Saberian, Eliza L. Posada, Sylvia Opusunju, Jeffrey E. Gershenwald, Carlos A. Torres-Cabala, Elizabeth M. Burton, Rivka R. Colen, Jason T. Huse, Isabella C. Glitza Oliva, Caroline Chung, Mary Frances McAleer, Susan L. McGovern, Debra N. Yeboa, Betty Y. S. Kim, Sujit S. Prabhu, Ian E. McCutcheon, Jeffrey S. Weinberg, Frederick F. Lang, Hussein A. Tawbi, Jing Li, Lauren E. Haydu, Michael A. Davies, Sherise D. Ferguson

Summary: This study evaluates changes in clinical features and overall survival (OS) for patients with melanoma brain metastasis (MBM). The treatment options for MBM have significantly changed in the last decade, leading to improved OS. Factors associated with survival in MBM patients include patient age, primary tumor Breslow thickness, prior immunotherapy, leptomeningeal disease, symptomatic MBMs, and whole brain radiation therapy in the current era.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Cell Biology

Oesophageal glomus tumours: rare neoplasms with aggressive clinical behaviour

Jacqueline E. Birkness-Gartman, Sintawat Wangsiricharoen, Alexander J. Lazar, John M. Gross

Summary: This study describes the clinicopathologic features of three oesophageal glomus tumours diagnosed at two large academic institutions between 1984 and 2022. These tumours exhibited aggressive behavior with metastases to multiple sites. Management by a multidisciplinary sarcoma team is recommended for optimal outcome.

HISTOPATHOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Isabella C. Glitza Oliva, Sherise D. Ferguson, Roland Bassett Jr, Alexandra P. Foster, Ida John, Tarin D. Hennegan, Michelle Rohlfs, Jessie Richard, Masood Iqbal, Tina Dett, Carol Lacey, Natalie Jackson, Theresa Rodgers, Suzanne Phillips, Sheila Duncan, Lauren Haydu, Ruitao Lin, Rodabe N. Amaria, Michael K. Wong, Adi Diab, Cassian Yee, Sapna P. Patel, Jennifer L. McQuade, Grant M. Fischer, Ian E. McCutcheon, Barbara J. O'Brien, Sudhakar Tummala, Matthew Debnam, Nandita Guha-Thakurta, Jennifer A. Wargo, Elizabeth M. Burton, Hussein A. Tawbi, Michael A. Davies

Summary: This report presents the interim analysis results of an ongoing study on the use of concurrent intrathecal and intravenous nivolumab in patients with melanoma and leptomeningeal disease. The study aims to determine the safety and recommended dose of intrathecal nivolumab, with secondary endpoint being overall survival. Initial results suggest that concurrent IT and IV nivolumab is safe and feasible with potential efficacy in patients with melanoma LMD.

NATURE MEDICINE (2023)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Claus Garbe, Reinhard Dummer, Teresa Amaral, Rodabe N. Amaria, Paolo A. Ascierto, Elizabeth M. Burton, Brigitte Dreno, Alexander M. M. Eggermont, Axel Hauschild, Christoph Hoeller, Roland Kaufmann, Celeste Lebbe, Mario Mandala, Alexander M. Menzies, David Moreno, Olivier Michielin, Paul Nathan, Sapna P. Patel, Caroline Robert, Dirk Schadendorf, Paul C. Lorigan, Richard A. Scolyer, Hussein A. Tawbi, Bart A. van de Wiel, Christian Blank, Georgina V. Long

Summary: Individuals with cutaneous melanoma who receive neoadjuvant immunotherapy demonstrate significant improvement, which should be included in standard care.

NATURE MEDICINE (2023)

添加到收藏夹

Article Oncology

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

Gabriele Romano, Francesca Paradiso, Peng Li, Pooja Shukla, Lindsay N. Barger, Olivia El Naggar, John P. Miller, Roger J. Liang, Timothy L. Helms, Alexander J. Lazar, Jennifer A. Wargo, Francesca Taraballi, James C. Costello, Lawrence N. Kwong

Summary: Patients with BRAF-mutant melanoma respond well to combined BRAF and MEK inhibition, but relapse is common within 2 years. Minimal residual disease (MRD), which consists of drug-tolerant tumor cells in a dormant state, is a major cause of drug resistance. By studying a mouse model, researchers found that sustaining chemokine signaling can impair MRD maintenance by increasing the recruitment of effector T cells.

CANCER IMMUNOLOGY RESEARCH (2023)

添加到收藏夹

Review Oncology

Targeting the Molecular and Immunologic Features of Leiomyosarcoma

Brandon M. Cope, Raymond S. Traweek, Rossana Lazcano, Emily Z. Keung, Alexander J. Lazar, Christina L. Roland, Elise F. Nassif

Summary: Immunotherapy has greatly improved cancer care, but leiomyosarcoma is not responsive to early immune-based therapies. This review discusses the results of immunotherapy trials in leiomyosarcoma and highlights the differences between soft-tissue and uterine leiomyosarcomas. It also explores the molecular subgroups of leiomyosarcomas and their impact on response to immune checkpoint blockade, proposing future directions for improving immunotherapy in leiomyosarcoma patients. Leiomyosarcoma is a rare and aggressive tumor with low tumor mutational burden, frequent alterations in certain genes, and a highly infiltrated immune microenvironment. This review provides insights for the development of biomarker-based immune therapies.

CANCERS (2023)

添加到收藏夹

Article Dermatology

Telomerase reverse transcriptase immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma

Woo Cheal Cho, Wen Li, Jun Gu, Wei-Lien Wang, Jing Ning, Steven Sfamenos, Pavandeep Gill, Priyadharsini Nagarajan, Jonathan L. Curry, Alexander J. Lazar, Victor G. Prieto, Carlos A. Torres-Cabala, Phyu P. Aung

Summary: The clinical utility of TERT IHC to predict TGA status in AMs appears to be limited given its low specificity and positive predictive value.

JOURNAL OF CUTANEOUS PATHOLOGY (2023)

添加到收藏夹

Meeting Abstract Oncology

The epigenetic impact and therapeutic opportunity of AR-directed therapy for desmoplastic small round cell tumor

Danh D. Truong, Salah-Eddine Lamhamedi-Cherradi, Mayinuer Maitituoheti, Hannah C. Beird, Chia-Chin Wu, Sandhya Krishnan, Davis Ingram, P. Andrew Futreal, Mark Titus, Alexander Lazar, Kunal Rai, A. Robert MacLeod, Najat C. Daw, Andrea Hayes, Joseph Ludwig

CANCER RESEARCH (2023)

添加到收藏夹

Meeting Abstract Medicine, Research & Experimental

TRPS1 Expression is a Marker for Malignancy in Peripheral Nerve Sheath Tumors

Rossana Lazcano, Davis Ingram, Alexander Lazar, Wei-Lien (Billy) Wang, Jeffrey Cloutier

LABORATORY INVESTIGATION (2023)

添加到收藏夹

Meeting Abstract Medicine, Research & Experimental

Improved Pathological Response in Undifferentiated Pleomorphic Sarcoma (UPS) Treated by Concurrent Immunotherapy and Radiation Therapy (RT) Compared with Radiation Therapy Alone

Rossana Lazcano, Raymond Traweek, Davis Ingram, Khalida Wani, B. Ashleigh Guadagnolo, Ahsan Farooqi, Christina Roland, Emily Keung, Andrew Bishop, Wei-Lien (Billy) Wang, Elise Nassif, Alexander Lazar

LABORATORY INVESTIGATION (2023)

添加到收藏夹

Meeting Abstract Medicine, Research & Experimental

GPNMB Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor (PEComa)

Sintawat Wangsiricharoen, Davis Ingram, Alexander Lazar, Wei-Lien (Billy) Wang

LABORATORY INVESTIGATION (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.